STOCK TITAN

ANGLE PLC ORD - $ANPCF STOCK NEWS

Welcome to our dedicated page for ANGLE PLC ORD news (Ticker: $ANPCF), a resource for investors and traders seeking the latest updates and insights on ANGLE PLC ORD stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANGLE PLC ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANGLE PLC ORD's position in the market.

Rhea-AI Summary
ANGLE plc has secured US and EU patents for its CellKeep slide, reducing over 70% of CTC cell loss during microscopy, enhancing assay sensitivity. The innovative device improves CTC attachment to slides, increasing cell preservation and reducing costs. The technology significantly boosts identification rates of CTCs and biomarkers, advancing precision medicine for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
ANGLE plc (ANPCY) presents Parsortix HER2 assay at AACR Annual Meeting 2024, showcasing a novel assay for HER2 assessment on circulating tumor cells. The assay, developed in collaboration with BioView, aims to evaluate HER2 gene amplification and protein expression in metastatic breast cancer patients. The presented data demonstrates successful identification of HER2 positive CTCs, potentially benefiting patients who may require HER2-targeted therapies. Liquid biopsy evaluation offers a minimally invasive technique for monitoring HER2 status over time, providing valuable data for treatment decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
ANGLE plc showcases Parsortix system and assays at a leading European Breast Cancer Conference. The company presents two posters highlighting the utility of its new Portrait+ CTC Staining Kit and Portrait HER2 assay. ANGLE's technology enables comprehensive analysis of circulating tumor cells, including mesenchymal CTCs and CTC clusters, crucial for cancer progression and metastasis. The company's IF assay for HER2 status in CTCs offers a minimally invasive alternative to tissue biopsies, allowing for dynamic monitoring and potential clinical decision-making in metastatic breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ANGLE plc announces breakthrough data from a newly established workflow for real-time parallel Next Generation Sequencing (NGS) DNA analysis of both ctDNA and CTCs from a single tube of patient blood. The peer-reviewed paper in 'Current Issues in Molecular Biology' highlights the potential utility of Parsortix CTC harvest in precision oncology. The study showcases the benefits of utilizing the Parsortix system for downstream molecular analysis across various cancer types. The findings demonstrate the value of a dual analyte approach for both CTCs and ctDNA in informing prognosis, treatment selection, monitoring of treatment resistance, and disease relapse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
ANGLE PLC ORD

OTC:ANPCF

ANPCF Rankings

ANPCF Stock Data

60.98M
201.15M
10.74%
27.5%
Diagnostics & Research
Healthcare
Link
United States of America
Guildford